Accessibility Menu
QHSLab logo

QHSLab(OTC) USAQ

Market Cap$5.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 Year-61%
1 Year+74%
1 Month+31%
$0.35
+16%
+0.05Today
QHSLab last closing stock price
MetricPriceDate
Last closeUSD 0.352026-07-27
QHSLab stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+31.32%USD 0.272026-07-20
1 month+31.32%USD 0.272026-06-25
3 month-36.48%USD 0.552026-04-28
Year to date-42.56%USD 0.612025-12-31
1 year+74%USD 0.202025-07-25
3 year+364%USD 0.082023-07-28
5 year-60.89%USD 0.892021-07-28
Since inception-99.98%USD 1,525.001992-04-07

QHSLab Financials at a Glance

Market Cap

$5.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.78M

Net Income (TTM)

$433.12K

EPS (TTM)

$0.02

P/E Ratio

15.40

Dividend

$0.00

Beta (Volatility)

-0.39 (Low)

Price

$0.35

Volume

1,059

Open

$0.31

Previous Close

$0.35

Daily Range

$0.31 - $0.35

52-Week Range

$0.08 - $1.14

Estimated Earnings Date

Aug 19, 2026

USAQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About QHSLab

QHSLab helps doctors manage allergies and chronic diseases in their clinics. Its software and diagnostic kits support early detection and ongoing care. These tools make it easier for primary care doctors to treat patients directly.

Gadgets, Kits, and Clicks: What QHSLab Sells

  • Allergy Diagnostic Kits: Tools for doctors to test patients for allergies in-office (approximately 32.7% of Q2 2025 revenue).
  • Integrated Service Program: Digital health assessments and workflow support for clinics. Q2 2025 ISP revenue was $263,628 out of $605,446 total revenue.
  • Immunotherapy Treatments: Allergy treatments for patients, provided through primary care. Q2 2025 Immunotherapy Treatment Sales were $119,885 out of $605,446 total revenue.
  • QHSLab SaaS Platform: Cloud-based software for storing patient data and supporting remote care. Q2 2025 Subscription Revenue was $9,252 out of $605,446 total revenue.
  • Clinical Research Services: Software-driven support for medical studies. Six-month 2025 Clinical Study Revenue was $89,100 out of $1,250,865 total revenue.

Growth Spurts and Strategic Moves

  • Changed name from USA Equities to QHSLab in April 2022 to reflect new focus.
  • Formed a strategic alliance with Medical License Factory.
  • Launched clinical research services in early 2025, adding a new revenue stream.
  • Expanded QHSLab platform features and digital medicine programs throughout 2024–2025.

Why QHSLab Stands Out (Without Allergic Reactions)

QHSLab lets primary care doctors offer specialist-level allergy and chronic care in their own clinics. Its software supports remote patient monitoring and digital health assessments, helping clinics qualify for insurance reimbursements. The company’s single-segment model keeps operations focused and integrated.

Five Things You Need to Know

  • Q2 2025 revenue was $605,446, up 28.0% from Q2 2024.
  • Gross margin reached 65.9% in Q2 2025, up from 62.2% a year earlier.
  • Net loss for Q2 2025 was $52,958, compared to $2,890 in Q2 2024.
  • Cash flow from operations was $127,033 in Q2 2025, up 45.4% year-on-year.
  • All major debt is in default as of June 30, 2025, with forbearance agreements in place.

Bottom Line

QHSLab has shifted from traditional medical devices to digital health and allergy care. The company’s growth comes with financial risks, but its products help primary care doctors deliver more in-house care.

AI Generated • Apr 16, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

12

CEO

Troy Grogan

Website

www.usaqcorp.com

Headquarters

West Palm Beach, FL 33407, US

USAQ Financials

Key Financial Metrics (TTM)

Gross Margin

66.08%

Operating Margin

1.76%

Net Income Margin

15.61%

Return on Equity

91.63%

Return on Capital

7.98%

Return on Assets

22.93%

Earnings Yield

6.49%

Dividend Yield

0.00%

Payout Ratio

6.84%

Stock Overview

Market Cap

$5.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.03M

Volume

1.06K

Avg. Volume

3.34K

Financials (TTM)

Gross Profit

$1.83M

Operating Income

$48.90K

EBITDA

$684.60K

Operating Cash Flow

$27.43K

Capital Expenditure

-$3.00

Free Cash Flow

$27.43K

Cash & ST Invst.

$362.09K

Total Debt

$130.18K

QHSLab Performance Analysis

QHSLab annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,243,186-12.1%
20232023-12-31USD 1,408,99513.3%
20242024-12-31USD 2,131,92651.3%
20252025-12-31USD 2,691,74126.3%
QHSLab sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-6.2%
Q32025-09-3021.7%
Q42025-12-31-4.5%
Q12026-03-313.5%
QHSLab annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.1113.0%
20232023-12-31USD -0.05-55.1%
20242024-12-31USD -0.03-49.3%
20252025-12-31USD 0.02N/A
QHSLab sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.8%
Q32025-09-30136.2%
Q42025-12-311670.6%
Q12026-03-31-122.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$728.69K

+12.9%

Gross Profit

$452.78K

+5.3%

Gross Margin

62.14%

N/A

Market Cap

$5.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$435.95K

N/A

Employees

12

N/A

Net Income

-$103.91K

-30.5%

EBITDA

-$76.35K

-410.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$362.09K

+493.0%

Total Debt

$130.18K

-91.9%

Accounts Receivable

$201.20K

+3.2%

Inventory

$27.52K

-5.7%

Long Term Debt

$0.00

N/A

Short Term Debt

$130.18K

-91.9%

Return on Assets

22.93%

N/A

Return on Invested Capital

3.22%

N/A

Free Cash Flow

-$200.24K

-304.1%

Operating Cash Flow

-$200.24K

-304.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUMDNu-Med Plus, Inc.
$0.02+0.00%
CSOCCaduceus Software Systems Corp.
$0.00+0.00%
APLIFAppili Therapeutics Inc
$0.01+0.00%
CVGRFCity View Green Holdings Inc.
$0.03+2.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About USAQ

What is the current price of QHSLab?

QHSLab is trading at $0.35 per share.

What is the 52-week range for QHSLab?

Over the past 52 weeks, QHSLab has traded between $0.08 and $1.14.

How much debt does QHSLab have?

As of the most recent reporting period, QHSLab reported total debt of $130.18K.

How much cash does QHSLab have on hand?

QHSLab reported $362.09K in cash and cash equivalents in its most recent financial results.

What is QHSLab’s dividend yield?

QHSLab does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services